Schistosomes: the road from host-parasite interactions to vaccines in clinical trials, Trends Parasitol, vol.21, issue.3, p.15734662, 2005. ,
Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis, Lancet, vol.365, issue.9470, pp.1561-1570, 2005. ,
Diagnosis and management of schistosomiasis, BMJ, vol.342, issue.2651, p.3230106, 2011. ,
, Schistosomiasis: number of people treated worldwide in 2013, WHO, vol.90, issue.5, p.25638822, 2015.
Schistosomiasis vaccines: where do we stand? Parasit Vectors, vol.9, p.5045607, 2016. ,
Pivotal roles of the parasite PGD2 synthase and of the host D prostanoid receptor 1 in schistosome immune evasion, Eur J Immunol, vol.33, issue.10, p.14515260, 2003. ,
Functional specific binding of testosterone to Schistosoma haematobium 28-kilodalton glutathione S-transferase, Infect Immun, vol.70, issue.2, p.127730, 2002. ,
Glutathione transferases from parasites: a biochemical view, Acta Trop, vol.105, issue.2, p.17897613, 2008. ,
Crystal structure of the 28 kDa glutathione S-transferase from Schistosoma haematobium, Biochemistry, vol.42, issue.34, pp.10084-94, 2003. ,
Vaccine potential of a recombinant glutathione S-transferase cloned from Schistosoma haematobium in primates experimentally infected with an homologous challenge, Vaccine, vol.17, issue.4, p.9987169, 1999. ,
Control of schistosomiasis pathology by combination of Sm28GST DNA immunization and praziquantel treatment, J Infect Dis, vol.180, issue.2, pp.454-63, 1999. ,
Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis, PLoS Negl Trop Dis, vol.6, issue.7, p.3389022, 2012. ,
Schistosomiasis elimination strategies and potential role of a vaccine in achieving global health goals, Am J Trop Med Hyg, vol.90, issue.1, p.3886428, 2014. ,
, WHO. Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products-Sixth Report. WHO Technical Report Series, vol.3, issue.850, pp.97-137, 1995.
, Guidelines for Good Clinical Practice (3 errata post step 4 included). ICH Harmonised Tripartite Guideline, 1996.
Molecular cloning of a protective antigen of schistosomes, Nature, vol.326, issue.6109, p.2434863, 1987. ,
, NIAID) NIoAaID. DIVISION OF MICROBIOLOGY AND INFECTIOUS DISEASES (DMID) PEDIATRIC TOXICITY TABLES, 2007.
A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni, Rev Inst Med Trop Sao Paulo, vol.14, issue.6, 1972. ,
Evaluation of the Kato-Katz thick smear and formol ether sedimentation techniques for quantitative diagnosis of Schistosoma mansoni infection, Am J Trop Med Hyg, vol.57, issue.6, p.9430532, 1997. ,
Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial, Clin Infect Dis, vol.50, issue.9, pp.1205-1218, 2010. ,
Egg-hatching inhibition in mice immunized with recombinant Schistosoma bovis 28 kDa glutathione S-transferase, Parasite Immunol, vol.21, issue.7, p.10417668, 1999. ,
Sex-dependent neutralizing humoral response to Schistosoma mansoni 28GST antigen in infected human populations, J Infect Dis, vol.181, issue.5, pp.1855-1864, 2000. ,
The WHO ultrasonography protocol for assessing morbidity due to Schistosoma haematobium. Acceptance and evolution over 14 years. Systematic review, Parasitol Res, vol.114, issue.4, p.25711148, 2015. ,
Curr Drug Targets Immune Endocr Metabol Disord, vol.2, p.12476492, 2002. ,
A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection, Vaccine, vol.21, issue.5-6, p.12531651, 2003. ,
Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice, J Immunol, vol.163, issue.2, 1999. ,
Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium, PLoS Negl Trop Dis, vol.8, issue.7, p.25079601, 2014. ,
, , p.4117464
Integrated analysis of innate, Th1, Th2, Th17, and regulatory cytokines identifies changes in immune polarisation following treatment of human schistosomiasis, J Infect Dis, vol.208, issue.1, p.3666130, 2013. ,
Cytokine responses to the antischistosome vaccine candidate antigen glutathione-S-transferase vary with host age and are boosted by praziquantel treatment, PLoS Negl Trop Dis, vol.8, issue.5, p.4014416, 2014. ,
Gender-dependent specific immune response during chronic human Schistosomiasis haematobia, Clin Exp Immunol, vol.124, issue.1, p.1906031, 2001. ,
Immuno-epidemiology of human Schistosoma haematobium infection: preferential IgG3 antibody responsiveness to a recombinant antigen dependent on age and parasite burden, BMC Infect Dis, vol.6, p.1523344, 2006. ,
Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones, J Exp Med, vol.173, issue.3, p.2118815, 1991. ,
Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults, Vaccine, vol.34, issue.4, p.26571311, 2016. ,
Relationship of impairment of schistosome 28-kilodalton glutathione S-transferase (GST) activity to expression of immunity to Schistosoma mattheei in calves vaccinated with recombinant Schistosoma bovis 28-kilodalton GST, Infect Immun, vol.66, issue.3, p.108027, 1998. ,
Potential Mechanisms for IgG4 Inhibition of Immediate Hypersensitivity Reactions, Curr Allergy Asthma Rep, vol.16, issue.3, p.4759210, 2016. ,